louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06361225: Routine Use of RUSH Protocol in the Intensive Care Unit
Official title: Routine Use of RUSH Protocol in the Intensive Care Unit- Does it Influence Patient Management? Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: RUSH Protocol
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2024-04-11
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who were admitted to the intensive care unit for any reason and were evaluated daily using the RUSH protocol.

Brief summary: The RUSH protocol has been used for several years for the rapid evaluation of a patient admitted to the emergency room with shock. Traditionally, its use was especially common in trauma victims, but later its use was extended to patients admitted to the emergency room with shock from any reason. The protocol includes rapid assessment with the guideness of ultrasound of heart contraction, assessment for pleural effusions, assessment of intra-abdominal blood (FAST), diagnosis of venous thrombosis (DVT), and rulling out hydronephrosis. It can also add a pupil size assessment and an evaluation of the gallbladder and bile ducts, as well as the size of the bladder. In intensive care, we use this protocol (or part of it) for the evaluation of a patient who is deteriorating in the ICU for an unknown reason . In some patients we use this protocol as a routine part of the physical examination as part of the daily patient evaluation.

We would like to investigate whether the routine use of the RUSH protocol as part of the daily patient evaluation in the general intensive care unit will lead to any change in the patient's management.


Eligibility criteria: Inclusion Criteria:

* Patients who were admitted to the intensive care unit for any reason and were evaluated daily using the RUSH protocol.

Exclusion Criteria:Patients who were not evaluated using the RUSH protocol or for whom data were missing.

-

Primary outcomes:
measure: Change of patient medical therapy
timeFrame: from day 0 to day 3 of performing the RUSH protocol
measure: Performing unplanned laboratory tests
timeFrame: from day 0 to day 3 of performing the RUSH protocol
measure: Performing unplanned image tests
timeFrame: from day 0 to day 3 of performing the RUSH protocol
measure: Performing unplanned invasive procedure
timeFrame: from day 0 to day 3 of performing the RUSH protocol
Secondary outcomes:
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: Meir Medical Center
Study officials:
References:
Clinical trial NCT00213525: Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Controls
Official title: Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Healthy Controls
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Scleroderma
Lead sponsor: University Hospital, Rouen
Sponsor class: OTHER
First posted: 2005-09-21
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 76
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 100 Patients With Scleroderma and 300 Healthy Controls

Brief summary: Scleroderma is an autoimmune disease of unknown origin. Recently, the role of environmental factors, and particularly toxic drug exposure, in the genesis of scleroderma has been suggested.

This prompted us to conduct this prospective, case-control, multicentric study, including 2 groups of subjects:

* 100 patients with scleroderma
* 300 sex- and age-matched healthy controls. The aim of our study is to determine whether exposure to toxics is higher in patients with scleroderma compared with healthy controls.

Detailed description: The data of patients with scleroderma and healthy controls will be compared regarding:

* a standardized questionnaire about "cursus laboris" at initial inclusion
* a search for toxics in blood, urine and hair: at initial exvaluation, 6 month and 2 year-follow-up

Eligibility criteria: Inclusion Criteria:

* patients with scleroderma with:

  * age range : 18 to 76 years
  * written consent

Exclusion Criteria:

* patients with other connective-tissue disorders
* pregnant women
* patients with psychiatric conditions
* unwritten consent

Primary outcomes:
measure: Identification of environmental factor
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Rouen
country: France
facility: Rouen University Hospital
state: Rouen Cedex
Study officials:
affiliation: University Hospital, Rouen
name: Isabelle MARIE, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00268125: Phase 3 Study of Acupression's Bracelets in Nausea and Vomiting Induced by FEC100 Chemotherapy's Sort.
Official title: Evaluation of Acupression's Bracelets Associated to an Educational Step Versus Education Only in Nausea and Vomiting's Mastering Induced by FEC100 Chemotherapy's Sort.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Breast Neoplasms
Keywords: Breast Neoplasm
FEC100
Chemotherapy
acupression
bracelet
nausea
vomiting
Lead sponsor: Institut Claudius Regaud
Sponsor class: OTHER
First posted: 2005-12-22
Enrollment: 347
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to demonstrate a betterment of the digestive symptomatology by the anti-emetic acupression's bracelets's use associated with hygiene and dietetic advices.


Eligibility criteria: Inclusion Criteria:

* Woman
* Age \> 18 years
* Well-informed written consent, signed by the patient before the beginning of the study
* Breast cancer's diagnosis (operated or not)
* Forecast of a treatment by FEC100 chemotherapy's sort (D1=D21) during at least 3 cycles.
* Patient affiliated at a welfare or beneficiary from it
* Investigator estimates that the patient is able to conform with protocol's conditions and to respect them

Exclusion Criteria:

* Operated arm's lymphedema
* Wrist's morphology which cannot permit the bracelet's wearing (20 cm)
* D1=D15 FEC100's treatment
* Psychic incapability to sign a well-informed consent
* Refusal to give a written consent
* Patient under tutelage or guardianship
* Pregnant or breast-feeding woman
* Any clinical trial's participation which would impose nausea and vomiting's treatment modalities

Primary outcomes:
measure: Reduction of 15% of stage III/IV nausea and vomiting's incidence.
Secondary outcomes:
Other outcomes:
Locations:
city: Lille
country: France
facility: Centre Oscar Lambret
city: Strasbourg
country: France
facility: Centre Paul STRAUSS
city: Toulouse
country: France
facility: Institut Claudius Regaud
Study officials:
affiliation: Institut Claudius Regaud
name: Jean-Pierre DELORD, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04311125: Comparative Study of Minimally Invasive Surgical Approaches for Total Hip Arthroplasty
Official title: Comparative Study of Minimally Invasive Surgical Approaches for Total Hip Arthroplasty: a Biochemical, Imaging and Clinical Evaluation in the Early Postoperative Period
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hip Osteoarthritis
Hip Arthropathy
Minimal Invasive
Anterior Approach
Tissue Injury
Lead sponsor: National and Kapodistrian University of Athens
Sponsor class: OTHER
First posted: 2020-03-17
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Total hip arthroplasty is a method of choice for treating advanced osteoarthritis of the hip and one of the most frequent orthopedic procedures. Of all hip surgical approaches described, the tendency for minimally invasive techniques has been dominated over the last few years due to faster patient mobilization, reduced postoperative pain and need for blood transfusion. Two of the most common approaches used for minimally invasive total hip arthroplasty are: AMIS anterior approach and mini-posterior approach, which is a modification of the standard posterior approach. The purpose of this study is the biochemical, imaging and clinical evaluation of the tissue damage caused by the above-mentioned techniques of minimally invasive total hip arthroplasty.


Eligibility criteria: Inclusion Criteria:

* Patients that sign the Informed consent
* Patients aged 18 years and over who are going to undergo primary total hip arthroplasty

Exclusion Criteria:

I. Active infection II. Previous hip operation in any leg III. Any kind of operation the past 3 months IV. Obesity (BMI, Body Mass Index \>30) V. Autoimmune diseases or myositis of any etiology VI. Active cancer

Primary outcomes:
measure: Tissue damage change
timeFrame: Change from 6 to 24 and then 48 hours post-surgery
Secondary outcomes:
measure: Imaging
timeFrame: Day 30 after surgery
measure: Clinical Tests change
timeFrame: Change to clinical test from Day 2 to day 15 and then day 30 post-surgery
Other outcomes:
Locations:
city: Athens
country: Greece
facility: 2nd Department of Orthopaedics
state: Attika
Study officials:
References:
Clinical trial NCT02219425: Gene Expression Analysis of the Endometrium After Endometrial Biopsy in Fertile Women
Official title: Gene Expression Analysis of the Endometrium After Endometrial Biopsy in Fertile Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Keywords: Infertility
Endometrium
Endometrial biopsy
Gene expression
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2014-08-18
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the gene expression of the endometrium after an endometrial biopsy in fertile women using Next Generation Sequencing of total RNA.

Detailed description: An endometrial biopsy is done at cycle day LH+7 and repeated in the next cycle at cycle day LH+7.

Tissue is analysed and compared for changes in gene expression profile using Seq RNA

Eligibility criteria: Inclusion Criteria:

* Fertile women
* Age: 18-40 years
* BMI: 18-32
* Regular menstrual cycle
* No use of hormonal contraceptives or IUD the last 3 months

Exclusion Criteria:

* Patients in need of a interpreter
* Suspected intrauterine abnormalities
* Pregnancy

Primary outcomes:
measure: Gene Expression of the Endometrium after an endometrial biopsy
timeFrame: 1 month between each biopsy
Secondary outcomes:
Other outcomes:
Locations:
city: Horsens
country: Denmark
facility: Fertility Clinic Horsens Hospital
Study officials:
affiliation: Departement of Gynaecology and Obstetrics, Aarhus University
name: Axel Forman, MD, DMsc
role: STUDY_DIRECTOR
affiliation: Fertility Clinic Horsens Hospital, Aarhus University
name: Mia Steengaard Olesen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00737425: Safety and Efficacy Study of Pain Shield Device to Treat Subjects Following Laparoscopic-Assisted Abdominal Surgery
Official title: Evaluation of Safety and Efficacy of the PainShield Device for the Treatment of Subjects Who Underwent Laparoscopic-Assisted Abdominal Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Wounds
Keywords: laparoscopic-assisted surgery
abdominal
pain relief
wound healing
low intensity ultrasound
Lead sponsor: Shaare Zedek Medical Center
Sponsor class: OTHER
Collaborators: name: Nanovibronix
First posted: 2008-08-19
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate safety and efficacy of PainShield device, based on ultrasound technology, for postoperative pain relief and wound healing following a laparoscopic-assisted abdominal surgery.


Eligibility criteria: Inclusion Criteria:

* Subject's Age ≥ 18
* Subject is able, agrees and signs the Informed Consent Form
* Subject requires laparoscopic-assisted abdominal surgery
* Incision size following the laparoscopy between 4-7 cm

Exclusion Criteria:

* Epidural analgesia
* IV PCA
* Subject has any condition, which precludes compliance with study and/or device instructions
* Subject is currently participating in another clinical study.

Primary outcomes:
measure: Pain and discomfort will be measured using appropriate validated questionnaires.
timeFrame: Pain assessment will be performed daily
Secondary outcomes:
measure: Infections will be assessed by concomitant antibiotic intake
timeFrame: Concomitant medications will be assessed daily
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
Study officials:
References:
Clinical trial NCT06327425: MCG for Localization of Tachyarrhythmia's Origin
Official title: Magnetocardiography for Precise Identification of the Site of Origin of Tachyarrhythmia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Tachyarrhythmia
Atrial Flutter
Paroxysmal Supraventricular Tachycardia
Atrial Tachycardia
Atrial Fibrillation
Premature Ventricular Contraction
Lead sponsor: Qilu Hospital of Shandong University
Sponsor class: OTHER
First posted: 2024-03-25
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This is an exploratory research aiming to accurately identify the site of origin of tachyarrhythmia using Magnetocardiography (MCG), which will have guiding significance for early diagnosis, the formulation of treatment plans and preoperative positioning for radiofrequency ablation.


Eligibility criteria: Inclusion Criteria:

* Age 18-79 years old;
* Those whose conditions are comparatively stable and who have been diagnosed by an attending physician （or physicians with higher qualifications） with paroxysmal supraventricular tachycardia, atrial tachycardia, atrial flutter, atrial fibrillation, or premature ventricular contractions, and who are capable of performing MCG and cardiac electrophysiologic examinations after evaluation.
* Signed informed consent.

Exclusion Criteria:

* Those with known structural heart disease such as cardiomyopathy and valvular disease;
* Those with history of other cardiovascular diseases such as pulmonary embolism and aortic dissection;
* Those with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications;
* Those with obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply;
* Those with Obese (BMI\>30kg/cm2) or underweight (BMI\<18kg/cm2);
* Those with malignant tumors;
* Professional athletes, pregnant or breastfeeding women, alcoholics;
* Those with acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.;
* Those with infectious diseases or communicable diseases;
* Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.;
* Unable to or fail to cooperate with the corresponding research requirements.

Primary outcomes:
measure: Efficacy of MCG to detect the site of origin of Tachyarrhythmia using cardiac electrophysiology as a reference standard.
timeFrame: 12 month course of the disease
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: China, Shandong Qilu Hospital of Shandong University
state: Shandong
Study officials:
affiliation: Qliu Hospital of Shandong University
name: Yuguo Chen, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05790525: Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy
Official title: Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Helicobacter Pylori
Keywords: Oral Helicobacter pylori
Helicobacter pylori gastric
Eradication rate of Helicobacter pylori in the stomach
Lead sponsor: Xijing Hospital of Digestive Diseases
Sponsor class: OTHER
First posted: 2023-03-30
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to assess the effect of oral Helicobacter pylori infection on the efficacy of gastric Helicobacter pylori infection eradication. Patients diagnosed with gastric Helicobacter pylori infection are tested for oral Helicobacter pylori and given standard bismuth quadruple therapy, with a urea breath test, a rapid urease test, or a Helicobacter pylori stool antigen test to confirm gastric Helicobacter pylori eradication at week 6 follow-up, and an oral Helicobacter pylori test kit to confirm oral Helicobacter pylori eradication.


Eligibility criteria: Inclusion Criteria:

1. Age between 18\~70 ,both gender.
2. Initial diagnosis of stomach Helicobacter pylori infection or never had Helicobacter pylori infection.
3. Have not received dental care or systemic periodontal basic treatment in the past 1 year.

Exclusion Criteria:

1. Those who have contraindications to the drugs used in this institute or are allergic to the drugs used.
2. There is serious organ damage and complications (such as cirrhosis, uremia, etc.), severe or unstable cardiopulmonary or endocrine diseases.
3. Ongoing use of antiulcer medications (including PPIs taken within 2 weeks before Helicobacter pylori infection testing), antibiotics, or bismuth complexes (more than 3 times/week before screening).
4. Those with severe oral diseases and malignant tumors of the mouth.
5. Women planning pregnancy, pregnancy and breastfeeding.
6. Previously had upper gastrointestinal surgery.
7. Those who do not take their medication on time.
8. Refusal to sign informed consent.

Primary outcomes:
measure: Eradication rate of Helicobacter pylori in the stomach
timeFrame: 28 days after treatment
Secondary outcomes:
measure: Oral Helicobacter pylori conversion rate
timeFrame: 28 days after treatment
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hosipital of Digestive Disease
state: Shaanxi
Study officials:
affiliation: Xijing Hosipital of Digestive Disease
name: Yongquan Shi, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00100425: Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome
Official title: Central Nervous System Modulation of Visceral Pain in Persian Gulf War Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Irritable Bowel Syndrome
Keywords: Irritable Bowel Syndrome
Visceral Hypersensitivity
Visceral Pain
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2004-12-31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 72
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to provide new information and to determine which kinds of brief, tolerable, experimental pain are affected by the drugs being studied in patients with irritable bowel syndrome, a disease that causes chronic abdominal pain. The effects of dextromethorphan, naloxone, and fentanyl on experimental pain stimuli will be tested in these studies to better understand what causes irritable bowel syndrome.


Eligibility criteria: * Patients with irritable bowel syndrome and healthy pain-free individuals (as controls) will be studied.
* No medical condition that would contraindicate use of dextromethorphan, fentanyl or naloxone.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: Malcolm Randall VA Medical Center
state: Florida
Study officials:
References:
Clinical trial NCT04391725: Guided Tissue Regeneration in Healing of Through and Through Periapical Lesion
Official title: Healing Following Use Of Injectable Platelet Rich Fibrin With Collagen During Surgery In Through And Through Periapical Lesions
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Periapical Lesion
Lead sponsor: Postgraduate Institute of Dental Sciences Rohtak
Sponsor class: OTHER
First posted: 2020-05-18
Enrollment: 32
Sex: ALL
Minimum age (years): 16
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Aim of this study is to evaluate the effect of i-PRF in the healing of through and through periapical lesion after periradicular surgery

Detailed description: Detailed patient examination will be carried out and those satisfying inclusion criteria will be enrolled in the study. Written informed consent will be obtained and patients will be randomly allocated to two groups. Entire surgical procedure will be carried out by single operator. After complete elevation of the flap, debridement (periradicular curettage -enucleation) of the bony lesion will be performed. 3 mm root-tip resection will be performed and root end cavity will be prepared using an ultrasonic diamond-coated retrotip. Root end filling will be done with mineral trioxide aggregate (MTA). In test group The i-PRF will be produced and incorporated with collagen will be used to fill into the defect. In the control group, no guided tissue regeneration technique will be used. Flap will be re-positioned and sutured using nonabsorbable 4-0 silk sutures.Sutures will be removed 4-7 days postoperatively.

Eligibility criteria: Inclusion Criteria:

* Patients of age 16-55 years with a clinical \& radiographic diagnosis of through and through periradicular lesion using CBCT
* Negative response to sensitivity tests with radiographic evidence of periapical radiolucency.
* Failed previous root canal treatment primary or secondary with purulent discharge and radiographic evidence of periapical pathology.
* The teeth must have adequate final restoration with no clinical evidence of coronal leakage.

Exclusion Criteria:

* Unrestorable tooth.
* Fractured / perforated tooth.
* Systemic diseases contraindicating surgical procedures or with potential to affect healing.
* Teeth with deep pockets.
* Patient requiring antibiotic premedication.
* Patients with history of antibiotic use in last 3 months.
* Smokers

Primary outcomes:
measure: change from baseline in periapical radiolucency at 12 months
timeFrame: baseline to 12 months
Secondary outcomes:
measure: change in Quality of life from baseline to 7 days
timeFrame: postoperative Day 1 to day 7
Other outcomes:
Locations:
city: Rohtak
country: India
facility: Sanjay Tewari
state: Haryana
Study officials:
References: